Literature DB >> 11895909

Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.

José M García-Castellano1, Alberto Villanueva, John H Healey, Rebecca Sowers, Carlos Cordon-Cardo, Andrew Huvos, Joseph R Bertino, Paul Meyers, Richard Gorlick.   

Abstract

PURPOSE: Methylthioadenosine phosphorylase (MTAP) is an enzyme essential in the salvage of cellular adenine and methionine synthesis. The MTAP gene is located in the 9p21 chromosomal region and its loss is frequently associated with deletion of the tumor suppressor genes p15(INK4b) and p16(INK4a). The aim of this study was to investigate the frequency of molecular alterations in MTAP in osteosarcoma. EXPERIMENTAL
DESIGN: Samples from patients with high-grade osteosarcoma (n = 96) and three osteosarcoma cell lines (HOS, SaOS-2, and U2OS) were analyzed. Genomic DNA was analyzed for MTAP gene deletions by PCR, RNA expression was measured by semiquantitative reverse transcription-PCR, and the protein levels were measured by immunohistochemistry. RESULT: Deletion of at least one MTAP exon was found in 36 of 96 (37.5%) osteosarcoma patient samples and in one of the three cell lines (HOS). In all cases in which an MTAP gene deletion was observed, there was absence of detectable mRNA and protein. Furthermore, in four osteosarcoma patients, an MTAP deletion which was not evident at diagnosis was detected in subsequent tumor samples.
CONCLUSIONS: The MTAP gene is commonly deleted in osteosarcoma patient samples, leading to an absence of mRNA and protein expression; these results indicate that inhibitors of de novo purine synthesis or methionine depletion may be effective as treatments for osteosarcoma patients whose tumors fail to express MTAP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895909

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

1.  Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma.

Authors:  Yuwaraj Kadariya; Bu Yin; Baiqing Tang; Susan A Shinton; Eoin P Quinlivan; Xiang Hua; Andres Klein-Szanto; Tahseen I Al-Saleem; Craig H Bassing; Richard R Hardy; Warren D Kruger
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

2.  Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine.

Authors:  Baiqing Tang; Hyung-Ok Lee; Serim S An; Kathy Q Cai; Warren D Kruger
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

3.  Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.

Authors:  Xiaohong Rose Yang; Xueying Liang; Ruth M Pfeiffer; William Wheeler; Dennis Maeder; Laurie Burdette; Meredith Yeager; Stephen Chanock; Margaret A Tucker; Alisa M Goldstein
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

4.  Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.

Authors:  Baiqing Tang; Joseph R Testa; Warren D Kruger
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

Review 5.  6-thioguanine: a drug with unrealized potential for cancer therapy.

Authors:  Pashna N Munshi; Martin Lubin; Joseph R Bertino
Journal:  Oncologist       Date:  2014-06-13

6.  Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).

Authors:  Georgi Kirovski; Axel P Stevens; Barbara Czech; Katja Dettmer; Thomas S Weiss; Peter Wild; Arndt Hartmann; Anja K Bosserhoff; Peter J Oefner; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2011-01-28       Impact factor: 4.307

7.  Chemical genetic screening for compounds that preferentially inhibit growth of methylthioadenosine phosphorylase (MTAP)-deficient Saccharomyces cerevisiae.

Authors:  Yuwaraj Kadariya; Baiqing Tang; Cynthia B Myers; Jami Fukui; Jeffrey R Peterson; Warren D Kruger
Journal:  J Biomol Screen       Date:  2010-12-03

8.  Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.

Authors:  Iris Behrmann; Susanne Wallner; Waraporn Komyod; Peter C Heinrich; Marion Schuierer; Reinhard Buettner; Anja-Katrin Bosserhoff
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

9.  A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.

Authors:  Hedy Lee Kindler; Howard A Burris; Alan B Sandler; Ira Anton Oliff
Journal:  Invest New Drugs       Date:  2008-07-11       Impact factor: 3.850

10.  Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.

Authors:  J Mora; M Alaminos; C de Torres; P Illei; J Qin; N-K V Cheung; W L Gerald
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.